medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2010, Number 5

<< Back Next >>

Acta Pediatr Mex 2010; 31 (5)

Pediatric pharmacologic surveillance

Hernández-Solis M, Juárez-Olguín H

Language: Spanish
References: 16
Page: 227-232
PDF size: 748.84 Kb.


ABSTRACT

Pharmacovigilance includes the detection, validation, understanding and prevention of drug adverse reactions (DAR), which result in unintentional negative responses to commonly used drugs in therapeutic doses. The impact of DAR on health costs is illustrated by the fact that nearly 5% of hospitalizations are due to them. The lack of studies on pediatric populations concerning this issue is the reason for extrapolating intervation from studies done in adults. This extrapolation is not acceptable, because children are different and have a distinct drug metabolism, which differ from those in adults. Thence, the significance of pharmacovigilance as a mandatory procedure to improve pediatric medical attention is highlighted, a common practice in developed countries, while in ours, it is beginning to be implemented.


REFERENCES

  1. World Health Organization. The Uppsala Monitoring Centre. The Safety of Medicines In Public Health Programmes. Pharmacovigilance an essential tool. 2006

  2. World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions. Why do health professionals need to take action? 2002.

  3. World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products.2002.

  4. Tsouronis C. Adverse Drug Reactions and Drug-Induced Diseases. In: Troy DP, Hauber MJ, Klinger AM. (Eds). Textbook of Therapeutics: Drug and Disease Management. Lippinccont 8th Editión. Philadelphia: Williams & Wilkins; 2006. p. 31–4.

  5. Caldwell P, Murphy S, Butow P, Craig J. Clinical trials in children. Lancet 2004;364:803–11.

  6. Sammons H, Choonara I. What is happening to improve drug therapy in children? Paediatr Child Health 2007;17(3):108-10.

  7. World Health Organization. Promoting Safety of Medicines For Children. 2007.

  8. Rodríguez B, García V, Giral B, Hernández S, Jasso G. Farmacovigilancia III. La experiencia Internacional. Revista Medica del IMSS 2005;43:131–40.

  9. World Health Organization. The Uppsala Monitoring Centre. UR 47 (The Uppsala Reporting 47). 2009 Acceso: Enero 20, 2010.

  10. Juárez OH, Flores PJ, Lares AI. Medicatión-related services in a Mexican pediatric hospital. Am J Pharm 2004;61:311-2.

  11. Juárez OH, Pérez GG, Flores PJ. Pharmacovigilance and pharmacoepidemiology of drugs in a Mexican pediatric hospital. A proposed guide. Pharm Word Sci 2007;29:43-6.

  12. Rodríguez B, García V, Giral B, Hernández , Jasso G. Farmacovigilancia I. El Inicio. Rev Méd IMSS 2004;42:327–9.

  13. Becerril M, Diaz A, Bondani A. Introducción a la Farmacovigilancia. Primera Edición. Mexico; D.F: Sistema Federal de Protección Sanitaria. Comisión Federal para la Protección contra Riesgos Sanitarios; 2003. p. 14.

  14. Jasso G, Castellanos S., Santos P. Importancia de la farmacovigilancia en pediatría. Bol Med Hosp Infant Méx 2009;66:213-28.

  15. Programa Permanente de Farmacovigilancia. Dirección Ejecutiva del Centro Nacional de farmacovigilancia. COFEPRISSSA. 2009.

  16. Hernández S, Rodriguez B, Jasso G. Farmacovigilancia IV: La experiencia Institucional. Rev Med IMSS 2005;43(2):257-66.




2020     |     www.medigraphic.com